The Union League of Philadelphia
140 South Broad Street
Philadelphia, PA 19102
Date: Friday, November 15th, 11:30 am to 1:00 pm
Leonard Mazur, Chairman of the Board, Citius Pharmaceuticals
Leonard Mazur, Chairman of the Board
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.
Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.
Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.
Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.
Citius is committed to developing therapies for unmet medical needs with cost-effective products in high growth categories with low developmental risk.
Mino-Lok product has advanced to Phase 3 clinical studies.
CITI-101 (Mino-Wrap) is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. More information on this product will be coming soon.
CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the high-potency steroid, halobetasol, with lidocaine.
Citius has an experienced management team with demonstrated success in developing and commercializing novel pharmaceutical products.
Show off your PSA pride with our custom PSA merchandise!
Select an item and complete the payment form. Then pick up your gift at our next event!